Close Menu
The Elite TimesThe Elite Times
  • Home
  • Entrepreneur
  • Finance
  • Fund
  • Investment
  • Marketing
  • Stock
  • World
  • Business

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

Visionary Entrepreneur Manuel Manzoni and International Taxation Expert Marco Scardeoni Partner to Drive Global Expansion through GCC Advisors

April 16, 2024

Help comes to Fort Worth businesses affected by explosion – NBC 5 Dallas-Fort Worth

March 29, 2024

Lawmakers claim ‘irresponsible’ withdrawal from Endowment Fund proceeds to pay full dividends

March 29, 2024
Facebook X (Twitter) Instagram
Facebook X (Twitter) Instagram
The Elite TimesThe Elite Times
  • Home
  • Entrepreneur

    21 Great Business Ideas for Nurse Entrepreneurs

    March 27, 2024

    EY announces 18 female entrepreneurs selected for EY Entrepreneurial Winning Women™ Asia-Pacific class of 2024 | EY

    March 27, 2024

    Victims of Baltimore bridge collapse include father of three and budding entrepreneur

    March 27, 2024

    Until April 2nd, get great discounts with lifetime access to this stock market app

    March 27, 2024

    Secure and reliable project management support for $25

    March 27, 2024
  • Finance

    Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

    March 26, 2024

    Reddit ignites resurgence in meme stocks, further sign of ‘bull market on all fronts’

    March 26, 2024

    Walmart stock plummets, retail giant expected to see further growth

    March 26, 2024

    Stocks soar as Wall Street looks to continue breaking records

    March 26, 2024

    Stocks soar as Wall Street looks to continue breaking records

    March 26, 2024
  • Fund

    Help comes to Fort Worth businesses affected by explosion – NBC 5 Dallas-Fort Worth

    March 29, 2024

    Lawmakers claim ‘irresponsible’ withdrawal from Endowment Fund proceeds to pay full dividends

    March 29, 2024

    The LDP slush fund scandal: What will make po

    March 29, 2024

    City of San Antonio seeks dismissal of Reproductive Justice Fund lawsuit

    March 29, 2024

    Clashes expected between Biden fundraisers and President Trump during preview visit to New York

    March 29, 2024
  • Investment

    Amazon (NASDAQ:AMZN) accelerates investment in humanity and accelerates AI drive

    March 28, 2024

    Recent trends in Kazakhstan’s investment situation

    March 28, 2024

    City of South Bend shares plans for Madison Lifestyle District with more than $330 million in private investment

    March 28, 2024

    OKX Ventures announces strategic investment in MyShell, a pioneer in AI-integrated Web3 technology

    March 28, 2024

    Reform of the EU Foreign Direct Investment Screening Regulation – How might M&A Transactions be impacted? | Mayer Brown

    March 28, 2024
  • Marketing

    Premium hospitality is on fire

    March 27, 2024

    S&P 500 sets record as Wall Street emerges from lull

    March 27, 2024

    DevvStream Announces Multi-Year Agreement to Sell CFR Credits with Major Logistics and Marketing Company

    March 27, 2024

    Global online dating services market by service (casual dating, matchmaking, niche dating), subscription (annual, monthly, quarterly), age group, and gender

    March 27, 2024

    Tower Federal Credit Union Receives Two CUNA Diamond Awards for Creative Excellence in Marketing

    March 27, 2024
  • Stock

    Forget Tesla: We think the ‘Magnificent Seven’ should replace this stock

    March 27, 2024

    Forget about Tesla: One of the unstoppable artificial intelligence (AI) stocks belongs to the ‘Magnificent Seven’ instead

    March 27, 2024

    2 Artificial Intelligence (AI) Stocks with Potential for Parabolic Growth

    March 27, 2024

    Mr. Powell’s comment

    March 27, 2024

    What you need to know about Trump Media’s stock debut

    March 27, 2024
  • World

    Take a look inside the New York Stock Exchange, the world’s largest stock market

    March 26, 2024

    China challenges Biden’s electric vehicle plan at World Trade Organization

    March 26, 2024

    Wolfspeed joins Senator Thom Tillis and key officials to conquer world’s largest and most advanced silicon carbide facility

    March 26, 2024

    Amy Brenneman, Raviv Ullman, Jeremy Love, cast and others in ‘Galilee’ world premiere, 34 years old

    March 26, 2024

    These beauty brands are among the most innovative companies in the world

    March 26, 2024
  • Business

    Canadian business leaders say housing should be a top federal budget priority

    March 27, 2024

    The power of mentorship in business

    March 27, 2024

    Los Angeles County business owner forced to pay damages after SWAT raid

    March 27, 2024

    Chinese President Xi meets with foreign business leaders amid economic uncertainty | Business and Economic News

    March 27, 2024

    China’s Xi Jinping meets with US business leaders in Beijing

    March 27, 2024
The Elite TimesThe Elite Times
Home»Finance»Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
Finance

Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

The Elite Times TeamBy The Elite Times TeamMarch 26, 2024No Comments7 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest WhatsApp Email

[ad_1]

Aaron Ondry joins us as Chief Financial Officer, bringing extensive leadership experience in financial management, strategic planning, commercial finance and capital allocation.

Key appointments will be added within the existing corporate leadership team, expanding capabilities and expertise from early discovery to commercialization.

Cranberry, NJ, March 26, 2024–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated late-stage biotechnology company, is developing gene therapy solutions for rare diseases with high unmet needs. We are driving sustainable pipelines and today announced the appointment of Aaron Ondry. , will aim to further evolve the corporate leadership team through his appointment as Chief Financial Officer and key appointments with existing team members. These leadership announcements strengthen and expand Rocket’s readiness for a planned transition to the commercial stage and continued development of the pipeline.

Aaron Ondry He joins Rocket as Chief Financial Officer with more than 20 years of experience in financial management, strategic planning, commercial finance, capital allocation, and M&A, having held multiple financial leadership positions across the pharmaceutical and biotech industries. Mr. Ondry most recently served as CFO of Mirati Therapeutics through the launch of KRAZATI® and the company’s acquisition by Bristol-Myers Squibb in January 2024. He brings valuable expertise to support Rocket’s commercial transition and growth trajectory, particularly strong financial acumen and outstanding operational management. ability. Prior to joining Mirati, Mr. Ondry also held senior management positions at Arena Pharmaceuticals, Alexion Pharmaceuticals and Regeneron Pharmaceuticals.

Key appointments within Rocket’s existing corporate leadership team include:

  • Kinnari Patel, PharmD, MBA; Appointed president, director of research and development, and chief operating officer. Dr. Patel will focus on research and development, overseeing research through late-stage development and manufacturing. Additionally, she will continue to maintain her position as COO and drive company operations aimed at advancing the company’s key strategic priorities.

  • Dr. Jonathan Schwartz, Appointed chief medical and gene therapy officer, his responsibilities span research and discovery and clinical development. Dr. Schwartz brings deep and experienced scientific and clinical thought leadership to continue developing and advancing Rocket’s current and future pipeline.

  • Mark White, MB.ChB, has been appointed General Manager, Commercial Affairs, leading Medical Affairs, Marketing, Commercial Operations, and Value & Access. Dr. White’s extensive drug development and franchise leadership experience, combined with the benefits of consolidating these capabilities under his leadership, will position Roquette for long-term success with highly complex therapies targeting rare diseases. can be accommodated.

  • Martin Wilson. J.D. has been appointed General Counsel and Chief Executive Officer and will lead legal affairs, compliance and corporate development. This evolution creates a newly integrated team aimed at advancing Rocket’s corporate strategy, led by Mr. Wilson’s strong legal and strategic acumen and experience.

“Today’s management announcements are particularly exciting as we expand our financial expertise with the addition of experienced financial leader Aaron Ondry as our Chief Financial Officer, as we move from a clinical organization to a commercial-stage genetics company. This highlights Rocket’s readiness as we transform into a treatment company,” said Gaurav Shah, MD. , CEO of Rocket Pharma. “Leveraging the wealth of talent and experience in our team, we are optimally positioning Rocket to achieve operational and commercial excellence, and to help patients with rare cardiovascular and hematological diseases. We look forward to continuing our strong momentum as we advance key pipelines for the

About Rocket Pharmaceuticals Co., Ltd.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated late-stage company driving a sustainable pipeline of investigational gene therapies designed to correct the root causes of complex and rare diseases. is a biotechnology company. Rocket’s innovative multi-platform approach allows us to design the best gene therapy for each indication, unlocking the potential to help people living with devastating rare diseases experience long, fulfilling lives. We can create some transformative options.

Rocket’s lentiviral (LV) vector-based gene therapy targets blood disorders, including Fanconi anemia, leukocyte adhesion deficiency I (LAD-I), a difficult-to-treat genetic disease that causes bone marrow failure and potentially cancer. The program consists of the latter half of the program. Pyruvate kinase deficiency (PKD), a severe childhood genetic disease that causes recurrent, life-threatening infections and is often fatal, is caused by a single gene that causes increased red blood cell destruction and mild to life-threatening anemia. Sexual red blood cell disease.

Our adeno-associated virus (AAV)-based cardiovascular portfolio includes a late-stage program in Danon’s disease, a severe heart failure condition that causes the heart to thicken, and an early program in clinical trials for PKP2 arrhythmogenic cardiomyopathy (ACM). It contains. , a preclinical program targeting BAG3-related dilated cardiomyopathy (DCM), a life-threatening heart failure disease that causes ventricular arrhythmias and sudden cardiac death, and heart failure disease that causes ventricular enlargement.

For more information about Rocket, please visit www.rocketpharma.com and follow us on LinkedIn, YouTube, and X.

Rocket’s Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding Rocket’s future expectations, plans and prospects that involve risks and uncertainties and if they do not materialize or prove to be inaccurate. , contains assumptions that our results may differ materially from those expressed or implied by the press release. Such a positive statement. The Company makes such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than historical facts contained in this release are forward-looking statements. These forward-looking statements include: “believe,” “expect,” “anticipate,” “intend,” “plan,” “will,” “estimate,” “seek,” ” “’would,’ ‘may,’ ‘suggest,’ or similar terms, variations of such terms, or negative forms of such terms. These forward-looking statements include: Including, but not limited to, statements regarding expectations. drug deficiency disease (PKD), Danon’s disease (DD) and other diseases; anticipated timing and data readouts of Roquette’s ongoing and planned clinical trials; anticipated regulatory responses and planned filings of Roquette; Key collaborations and vendors regarding the product candidate, including the timing and results of the development, the safety, efficacy, and timing of Rocket’s DD program, planned pivotal clinical trials, and related preclinical studies and clinical trials. Rocket’s ability to establish relationships, develop sales and marketing capabilities or enter into agreements with third parties to sell and market its product candidates and additional indications compatible with its gene therapy technology; Rocket’s ability to expand the pipeline to target. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee such results. Actual results may differ from these forward-looking statements as a result of a variety of important factors, including, but not limited to, Rocket’s dependence on third parties to develop, manufacture, market, sell and distribute its product candidates, and the outcome of litigation. The results may differ materially from those expressed in the description. unanticipated expenses, the activities of Rocket’s competitors (including decisions regarding the timing, pricing, and discounts of competing products), the development, acquisition, promotion, sufficient patient enrollment, and clinical development of Rocket’s product candidates; Rocket’s ability to successfully complete research, acquire additional businesses, form strategic alliances or create joint ventures and realize the benefits of such acquisitions, alliances or joint ventures, product candidates; Rocket’s ability to obtain and enforce patents to protect, and successfully defend. Unanticipated Third Party Infringement Claims, and the Risks Thereof, are discussed in Rocket’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 27, 2024. It is further explained in the section entitled “Risk Factors”. and subsequent filings with the SEC, including quarterly reports on Form 10-Q. Therefore, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date they are made, and Rocket undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. not.

View source version on businesswire.com. https://www.businesswire.com/news/home/20240326360522/ja/

contact address

media
Kevin Giordano
media@rocketpharma.com

Investor
brooks larmer
investor@rocketpharma.com



[ad_2]

Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous ArticleIndia is growing: GDP growth and inbound investment drive deals | White & Case LLP
Next Article One Reds fan celebrates his favorite day with a party
The Elite Times Team
  • Website

Related Posts

Reddit ignites resurgence in meme stocks, further sign of ‘bull market on all fronts’

March 26, 2024

Walmart stock plummets, retail giant expected to see further growth

March 26, 2024

Stocks soar as Wall Street looks to continue breaking records

March 26, 2024
Leave A Reply Cancel Reply

Demo
Latest Posts

21 Great Business Ideas for Nurse Entrepreneurs

March 27, 2024

EY announces 18 female entrepreneurs selected for EY Entrepreneurial Winning Women™ Asia-Pacific class of 2024 | EY

March 27, 2024

Victims of Baltimore bridge collapse include father of three and budding entrepreneur

March 27, 2024

Until April 2nd, get great discounts with lifetime access to this stock market app

March 27, 2024
Stay In Touch
  • Facebook
  • Twitter
  • Pinterest
  • Instagram
  • YouTube
  • Vimeo
Don't Miss

Stoughton man pleads guilty to COVID-19 business relief loan fraud scheme

By The Elite Times TeamMarch 17, 2024

[ad_1] A Stoughton man has pleaded guilty to participating in a COVID-19 business relief loan…

AstriVax rounds out management team with Chief Business Officer (CBO) Dr. Gregory Fanning

March 19, 2024

ESPN opens for business: How the coming months will shape the future of the sports TV giant

March 20, 2024

Subscribe to Updates

Get the latest creative news from SmartMag about art & design.

Demo
About Us
About Us

Welcome to [Your Website Name], your go-to source for comprehensive information on funds, investments, and the latest in stock news. We are dedicated to providing you with accurate, insightful, and up-to-date content to empower your financial decisions.

Facebook X (Twitter) Pinterest YouTube WhatsApp
Our Picks

Visionary Entrepreneur Manuel Manzoni and International Taxation Expert Marco Scardeoni Partner to Drive Global Expansion through GCC Advisors

April 16, 2024

Help comes to Fort Worth businesses affected by explosion – NBC 5 Dallas-Fort Worth

March 29, 2024

Lawmakers claim ‘irresponsible’ withdrawal from Endowment Fund proceeds to pay full dividends

March 29, 2024
Most Popular

Visionary Entrepreneur Manuel Manzoni and International Taxation Expert Marco Scardeoni Partner to Drive Global Expansion through GCC Advisors

April 16, 2024

Teenage Girl Finds Mom’s Debit Card, Spends $64,000 on Mobile Games

January 9, 2020

Apple’s Beats Studio Pro Headphones Listed in FCC Database Ahead of Launch

January 10, 2020
© 2025 theelitetimes. Designed by theelitetimes.
  • Home
  • About us
  • Contact us
  • DMCA
  • Privacy Policy

Type above and press Enter to search. Press Esc to cancel.